FGP
BIIB icon

Freestone Grove Partners’s Biogen BIIB Stock Holding History

Freestone Grove Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-187,608
Closed -$33M – 994
2025
Q4 		$33M Sell
187,608
-31,258
-14% -$5.11M 0.24% 133
2025
Q3 		$30.7M Buy
218,866
+107,862
+97% +$14.6M 0.23% 158
2025
Q2 		$13.9M Buy
+111,004
New +$13.8M 0.11% 241

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Freestone Grove Partners's BIIB Position: Q1 2026 in Review

Freestone Grove Partners sold out of Biogen (BIIB) in Q1 2026, closing a stake of 187,608 shares — an estimated $33M sold.

Freestone Grove Partners first reported a position in BIIB in Q2 2025 and held it in 3 quarters. The position peaked at $33M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Freestone Grove Partners reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 187,608 Biogen shares in Q1 2026, an estimated $33M.
  • Freestone Grove Partners first reported a position in Biogen in Q2 2025 and held it in 3 quarters.
  • Freestone Grove Partners's Biogen position peaked at $33M in Q4 2025.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.